Five Key Factors Weighing on Dendreon

Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for ProvengeĀ® [sipuleucel-T], the first active immunotherapy approved for the treatment of ca